SCHEMBL17582

SCHEMBL17582

CCOC(=O)C(Cc1ccnc(OC)c1)NC(=O)CNC(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLK5 Q9Y337 1/20 0.41
AAK1 Q2M2I8 1/20 0.41
ALDH1A1 P00352 4/20 0.38
PTPRB P23467 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 4/20 0.37
POLB P06746 1/20 0.37
MAPK1 P28482 1/20 0.37
TACR1 P25103 1/20 0.37
ACE P12821 1/20 0.37
CTSS P25774 3/20 0.37
CTSK P43235 3/20 0.37
CTSB P07858 2/20 0.37
TP53 P04637 1/20 0.37
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17583 1.00 KLK5 (0.41) KLK5AAK1ALDH1A1PTPRBMEN1
SCHEMBL14861192 0.83 KLK5 (0.51) KLK5AAK1ALDH1A1MEN1KMT2A
SCHEMBL16228244 0.83 KLK5 (0.51) KLK5AAK1ALDH1A1MEN1KMT2A
SCHEMBL17177 0.82 CACNA1B (0.49) KLK5POLBACECTSSCTSK
SCHEMBL17178 0.82 CACNA1B (0.49) KLK5POLBACECTSSCTSK
SCHEMBL1673615 0.81 KLK5 (0.56) KLK5MEN1KMT2AMAPTPOLB
SCHEMBL17681 0.81 LOX (0.48) ALDH1A1MAPTPOLBTP53GAA
SCHEMBL17682 0.81 LOX (0.48) ALDH1A1MAPTPOLBTP53GAA
SCHEMBL1673614 0.81 KLK5 (0.56) KLK5MEN1KMT2AMAPTPOLB
SCHEMBL17294 0.80 PTPRB (0.39) KLK5ALDH1A1PTPRBMAPTTACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 EP disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 KLK5 376/4885AAK1 178/4885ALDH1A1 3293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.